Latest Breaking News On - Robert gerwien - Page 1 : comparemela.com

Stock Market | Daily Herald

Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders

BOSTON (BUSINESS WIRE) Dec 15, 2021

Pear Announces Ohio Department of Mental Health and Addiction Services will Provide Access to Prescription Digital Therapeutics to Help Local Communities Continue Fight Against Opioid Addiction

Pear Therapeutics and Prescryptive Health Announce Formulary Coverage for Prescription Digital Therapeutics reSET® & reSET-O® for the Treatment of Substance and Opioid Use Disorders

Pear Therapeutics and Prescryptive Health Announce Formulary Coverage for Prescription Digital Therapeutics reSET® & reSET-O® for the Treatment of Substance and Opioid Use Disorders By Staff 2 seconds ago Prescryptive Health, a health intelligence platform focused on improving the prescription drug market and the pharmacy experience, teams with Pear to make innovative prescription digital therapeutics (PDTs) accessible to its members in recovery. Prescryptive Health will offer and administer Pear’s reSET® and reSET-O® through its digital platform as a covered standard pharmacy benefit for people with substance use disorder or opioid use disorder. BOSTON & SAN FRANCISCO & REDMOND, Wash.–(BUSINESS WIRE)–Pear Therapeutics, Inc. and Prescryptive Health today announced that Prescryptive, the first health intelligence platform, will offer and administer benefit coverage for reSET® and reSET-O®, the first two prescription digital therapeutics (PDTs) to receive authoriza

Pear Therapeutics Announces Second Closing of Series D Financing

Company adds a leading national Integrated Delivery Network (IDN) as a strategic investor. The financing supports Pear’s continued efforts to expand patient access for its portfolio of Prescription Digital Therapeutics (PDTs), including reSET®, reSET-O® and Somryst® treating addiction and insomnia conditions, respectively. BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced the second closing of its Series D financing. The second closing included a leading national Integrated Delivery Network (IDN) as a new strategic investor. The national IDN is investing $20 million, bringing the total Series D investment to $100 million. “Pear is pleased to add one of America’s leading health care providers and health plans to our distinguished list of investors as we continue to expand patient access to our FDA-authorized digital therapeutics,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. �